HIV-1-Infected Human Macrophages, by Secreting RANK-L, Contribute to Enhanced Osteoclast Recruitment.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
30 Apr 2020
Historique:
received: 29 03 2020
revised: 27 04 2020
accepted: 28 04 2020
entrez: 6 5 2020
pubmed: 6 5 2020
medline: 12 2 2021
Statut: epublish

Résumé

HIV-1 infection is frequently associated with low bone density, which can progress to osteoporosis leading to a high risk of fractures. Only a few mechanisms have been proposed to explain the enhanced osteolysis in the context of HIV-1 infection. As macrophages are involved in bone homeostasis and are critical host cells for HIV-1, we asked whether HIV-1-infected macrophages could participate in bone degradation. Upon infection, human macrophages acquired some osteoclast features: they became multinucleated, upregulated the osteoclast markers RhoE and β3 integrin, and organized their podosomes as ring superstructures resembling osteoclast sealing zones. However, HIV-1-infected macrophages were not fully differentiated in osteoclasts as they did not upregulate NFATc-1 transcription factor and were unable to degrade bone. Investigating whether infected macrophages participate indirectly to virus-induced osteolysis, we showed that they produce RANK-L, the key osteoclastogenic cytokine. RANK-L secreted by HIV-1-infected macrophages was not sufficient to stimulate multinucleation, but promoted the protease-dependent migration of osteoclast precursors. In conclusion, we propose that, by stimulating RANK-L secretion, HIV-1-infected macrophages contribute to create a microenvironment that favors the recruitment of osteoclasts, participating in bone disorders observed in HIV-1 infected patients.

Identifiants

pubmed: 32365752
pii: ijms21093154
doi: 10.3390/ijms21093154
pmc: PMC7246503
pii:
doi:

Substances chimiques

Biomarkers 0
RANK Ligand 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Agence Nationale de la Recherche
ID : ANR16-CE13-0005-01
Organisme : Agence Nationale de Recherches sur le Sida et les Hépatites Virales
ID : ANRS2014-CI-2, ANRS2014-049, ANRS2018-2
Organisme : Fondation de l'Avenir pour la Recherche Médicale Appliquée
ID : FRM DEQ2016 0334894
Organisme : Human Frontier Science Program
ID : RGP0035/2016

Références

Proc Natl Acad Sci U S A. 2019 Apr 9;116(15):7431-7438
pubmed: 30918127
Ann N Y Acad Sci. 2011 Dec;1240:14-7
pubmed: 22172034
Pflugers Arch. 2017 Apr;469(3-4):517-525
pubmed: 28247013
Science. 2000 Sep 1;289(5484):1504-8
pubmed: 10968780
J Med Virol. 2008 Sep;80(9):1507-14
pubmed: 18649336
Eur J Cell Biol. 2006 Apr;85(3-4):195-202
pubmed: 16546562
Blood. 2015 Mar 5;125(10):1611-22
pubmed: 25527710
Blood. 2004 Dec 15;104(13):4029-37
pubmed: 15308576
Am J Pathol. 2006 Sep;169(3):987-98
pubmed: 16936272
Cell Adh Migr. 2014;8(3):191-204
pubmed: 24714644
J Immunol. 2010 Jan 15;184(2):1049-61
pubmed: 20018633
Curr Treat Options Infect Dis. 2017 Mar;9(1):52-67
pubmed: 28413362
Dev Cell. 2002 Dec;3(6):889-901
pubmed: 12479813
Cell Host Microbe. 2014 Dec 10;16(6):711-21
pubmed: 25467409
J Bone Miner Res. 2017 Mar;32(3):431-433
pubmed: 28177151
Cell Rep. 2019 Mar 26;26(13):3586-3599.e7
pubmed: 30917314
Curr HIV/AIDS Rep. 2012 Mar;9(1):16-25
pubmed: 22179898
Biomaterials. 2019 Mar;196:51-66
pubmed: 29107337
Adv Exp Med Biol. 2007;602:15-21
pubmed: 17966383
Cell Adh Migr. 2014;8(3):179-91
pubmed: 24713854
FASEB J. 2013 Sep;27(9):3608-18
pubmed: 23742809
Mol Biol Cell. 2008 Jan;19(1):394-404
pubmed: 17978100
J Orthop Res. 2013 Feb;31(2):218-26
pubmed: 23281130
Mol Biol Cell. 2014 Feb;25(3):380-96
pubmed: 24284899
J Cell Sci. 2017 Jun 15;130(12):2026-2035
pubmed: 28473470
Nature. 2019 Apr;568(7753):541-545
pubmed: 30971820
J Cell Sci. 2006 Dec 1;119(Pt 23):4878-88
pubmed: 17105771
Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):E2556-E2565
pubmed: 29463701
AIDS. 2003 Sep 5;17(13):1917-23
pubmed: 12960824
Cancer Immunol Res. 2018 Nov;6(11):1337-1351
pubmed: 30181209
Drug Discov Today. 2016 Sep;21(9):1345-1354
pubmed: 27151158
Pharmacol Ther. 2017 Jun;174:43-54
pubmed: 28185913
Retrovirology. 2015 Feb 07;12:12
pubmed: 25809599
Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13848-53
pubmed: 20643942
J Med Virol. 2007 Oct;79(10):1446-54
pubmed: 17705184
Nat Commun. 2015 Sep 22;6:8282
pubmed: 26392000
Curr Opin HIV AIDS. 2014 Jan;9(1):17-26
pubmed: 24263798
AIDS. 2018 Apr 24;32(7):885-894
pubmed: 29424771
Nature. 2019 Aug;572(7771):670-675
pubmed: 31391580
Aging Cell. 2015 Aug;14(4):534-46
pubmed: 25847297
ACS Nano. 2017 Apr 25;11(4):4028-4040
pubmed: 28355484
J Bone Miner Metab. 2017 Mar;35(2):234-242
pubmed: 27026434
Curr Osteoporos Rep. 2017 Aug;15(4):385-395
pubmed: 28647885
Eur J Cell Biol. 2006 Apr;85(3-4):203-11
pubmed: 16360241
Nat Microbiol. 2019 Apr;4(4):633-644
pubmed: 30718846
Blood. 2008 Dec 15;112(13):5074-83
pubmed: 18768394
Proc Natl Acad Sci U S A. 2004 May 4;101(18):7070-5
pubmed: 15103018
J Immunol. 2013 Jan 15;190(2):605-12
pubmed: 23241888
J Neuroimmune Pharmacol. 2011 Dec;6(4):658-75
pubmed: 21789505
PLoS Pathog. 2014 Nov 13;10(10):e1004497
pubmed: 25393853
Ann N Y Acad Sci. 2007 Nov;1116:227-37
pubmed: 18083930
Int J Mol Med. 2003 Jan;11(1):17-21
pubmed: 12469211
J Cell Sci. 1995 Dec;108 ( Pt 12):3649-59
pubmed: 8719871
Traffic. 2005 Aug;6(8):682-94
pubmed: 15998323
Bone. 2008 Dec;43(6):976-82
pubmed: 18835590
Front Immunol. 2017 Nov 30;8:1698
pubmed: 29250073
Nat Immunol. 2018 May;19(5):475-486
pubmed: 29670239
Biomed Res Int. 2014;2014:731039
pubmed: 24719884
AIDS. 2010 Sep 10;24(14):2233-8
pubmed: 20616695
Cell Host Microbe. 2016 Mar 9;19(3):304-10
pubmed: 26962941
J Immunol. 2010 Jun 15;184(12):7030-9
pubmed: 20488787

Auteurs

Rémi Mascarau (R)

Institut de Pharmacologie et Biologie Structurale, Université de Toulouse, CNRS UMR 5089, Université Toulouse III Paul Sabatier, CEDEX 04, 31077 Toulouse, France.

Florent Bertrand (F)

Institut de Pharmacologie et Biologie Structurale, Université de Toulouse, CNRS UMR 5089, Université Toulouse III Paul Sabatier, CEDEX 04, 31077 Toulouse, France.

Arnaud Labrousse (A)

Institut de Pharmacologie et Biologie Structurale, Université de Toulouse, CNRS UMR 5089, Université Toulouse III Paul Sabatier, CEDEX 04, 31077 Toulouse, France.

Isabelle Gennero (I)

Centre de Physiopathologie de Toulouse-Purpan, INSERM-CNRS UMR 1043, Université Toulouse III Paul Sabatier, 31024 Toulouse, France.
Institut Fédératif de Biologie, Centre Hospitalier Universitaire Toulouse, 31059 Toulouse, France.

Renaud Poincloux (R)

Institut de Pharmacologie et Biologie Structurale, Université de Toulouse, CNRS UMR 5089, Université Toulouse III Paul Sabatier, CEDEX 04, 31077 Toulouse, France.
International Associated Laboratory (LIA) CNRS "IM-TB/HIV" (1167), 31077 Toulouse, France.
International Associated Laboratory (LIA) CNRS "IM-TB/HIV" (1167), Buenos Aires C1425AUM, Argentina.

Isabelle Maridonneau-Parini (I)

Institut de Pharmacologie et Biologie Structurale, Université de Toulouse, CNRS UMR 5089, Université Toulouse III Paul Sabatier, CEDEX 04, 31077 Toulouse, France.
International Associated Laboratory (LIA) CNRS "IM-TB/HIV" (1167), 31077 Toulouse, France.
International Associated Laboratory (LIA) CNRS "IM-TB/HIV" (1167), Buenos Aires C1425AUM, Argentina.

Brigitte Raynaud-Messina (B)

Institut de Pharmacologie et Biologie Structurale, Université de Toulouse, CNRS UMR 5089, Université Toulouse III Paul Sabatier, CEDEX 04, 31077 Toulouse, France.
International Associated Laboratory (LIA) CNRS "IM-TB/HIV" (1167), 31077 Toulouse, France.
International Associated Laboratory (LIA) CNRS "IM-TB/HIV" (1167), Buenos Aires C1425AUM, Argentina.

Christel Vérollet (C)

Institut de Pharmacologie et Biologie Structurale, Université de Toulouse, CNRS UMR 5089, Université Toulouse III Paul Sabatier, CEDEX 04, 31077 Toulouse, France.
International Associated Laboratory (LIA) CNRS "IM-TB/HIV" (1167), 31077 Toulouse, France.
International Associated Laboratory (LIA) CNRS "IM-TB/HIV" (1167), Buenos Aires C1425AUM, Argentina.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH